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d-Amino acids in peptide linkage are a noteworthy exception
from the universal homochirality of proteins and peptides.
[1]
The first animal peptide that was found to contain a d-amino
acid as the second residue was dermorphin, isolated from the
skin of a South American tree frog.
[2] This peptide binds with
high affinity to m-opiate receptors. The d-residue in this and re-
lated amphibian opioid peptides is essential for the biological
function, whereas the all-l-isomers lack activity.
Further studies led to the discovery of additional diastereo-
meric peptides from numerous sources,
[3] which include two
components, a natriuretic peptide and a b-defensin, from the
venom of the male platypus, a primitive mammal.
[4] All of
these peptides contain a single d-amino acid substitution in a
well-defined position, which is the second residue of the
mature product in all vertebrate peptides known to date.
Whenever the structure of the precursor polypeptides was de-
duced from cloned cDNAs, a codon for the corresponding l-
amino acid was present in the mRNA at the position where a
d-residue occurs in the mature form. This fact shows that the
d-residue is enzymatically introduced during a post-translation-
al event.
[5]
Fire-bellied toads (Bombina variegata, Bombina bombina as
well as Bombina orientalis) contain in their skin secretions
bombinins H, peptides with antibacterial and hemolytic prop-
erties,
[6] some of which contain a d-amino acid substitution;
indeed, both isomers coexist in the skin glands. The d-amino
acid at the second position gives rise to subtle changes in bio-
physical properties and folding propensity.
[7] More recently, the
d-amino acid was observed to affect both the target microbial
cell selectivity and membrane-perturbing activity of bombi-
nin H.
[8] The peptidyl-aminoacyl-l/d-isomerase (henceforth
briefly referred to as isomerase), which catalyses this post-
translational stereo-inversion, has been purified and character-
ized.
[9] Surprisingly, this protein, a 52 kDa glycoprotein, is appa-
rently excised from a polyprotein containing several isomerase
domains separated by short individual spacer sequences.
Genes coding for related proteins are present in several verte-
brate species.
In particular, the amino-terminal domain H of the human
IgG-Fcg binding protein
[10] is related to the frog skin enzyme,
and thus, could have isomerase activity. The similarity is high-
est in a central region, which contains two conserved histidine
residues as well as a pair of cysteines. Further studies have
shown that the Bombina isomerase is inactivated by diethyl-
pyrocarbonate, which indicates that one or two histidine resi-
dues indeed are part of the active site. The pH dependence of
the reaction rate, which shows a steep decline below pH 5.5,
supports this notion. If the isomerization reaction, which pro-
ceeds in both directions, is carried out in tritiated water, radio-
activity is incorporated into the second residue, which is an Ile
in bombinin H. This demonstrates that the change of chirality
proceeds through a deprotonation/protonation mechanism at
the a-carbon. Such a mechanism is also operative in other iso-
merases, for example, an epimerase from spider venom,
[11]
which is structurally unrelated to the Bombina isomerase, and
an isomerase from the venom of male platypus.
[12] The latter
could also involve at least one His as a catalytic base;
[13] its se-
quence, however, is not known at present. The enzymes from
hylid frogs, conus snails, and crustaceans as well as the isomer-
ase activity, which is likely present in mouse heart, are not yet
studied to sufficient detail.
[14]
Here, we have extended these studies in order to obtain a
closer insight into the reaction mechanism. For this purpose,
we performed the reaction catalysed by the frog isomerase in
2H2O. A comparison of the reaction rate with the rates of deu-
terium incorporation revealed that the sole product is deuter-
ated during early reaction stages (Figure S1 in the Supporting
Information). These observations are consistent with a classical
two-hydrogen-acceptor (two-base) mechanism (Scheme 1).
[15]
In D2O, the reaction was significantly retarded (by about three
times when compared to water). This effect suggests that
proton delivery to the a
2-carbon also significantly contributes
to the reaction rate. Moreover, the symmetry of the reaction is
shifted at the cost of the l!d reaction as indicated by the
equilibrium concentrations. This fact indicates that the action
of the bases is differentially impaired by the isotope effect.
Next, we synthesized two specifically designed planar sub-
strate analogues and tested their effect on the isomerization
reaction catalysed by the frog isomerase. Peptides Ile-D
2,3-Ala-
Gly-Pro-Val-Leu-amide (IDA) and Ile-D
2,3-Phe-Gly-Pro-Val-Leu-
amide (IDF) both contain at the second position an a,b-un-
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2 hybridised a-carbon,
which eventually could mimic potential enolate anion inter-
mediates (Scheme 2) or the planar transition states in a SN2-
type mechanism (concerted deprotonation/protonation). The
corresponding saturated peptides, IA and IF, are good sub-
strates of the isomerase, yet with vastly diverse catalytic effi-
ciencies ((kcat/KM)IF/(kcat/KM)IA 50). Compounds IDA and IDF ex-
erted a strong inhibitory effect independently of the direction
of the enzymatic reaction (Figure 1), that is, either l!d or vice
versa (Figure S2 in the Supporting Information).
Surprisingly, the experimental data indicated that the inhibi-
tion was not competitive; high substrate concentrations did
not restore enzymatic activity as it is the characteristics of
competitive inhibition (a Michaelis–Menten analysis of the data
in Figure 1 is shown in Figure S3 in the Supporting Informa-
tion). Furthermore, no evidence of reactivation of partly inhib-
ited enzyme was observed after 100-fold dilution into buffer.
Conversely, their action was virtually irreversible, and therefore,
probably indicative of tight, yet noncovalent binding of the
inhibitors.
[16] The determination of the release rates (off-rate) of
the inhibitors from the enzyme was, however, hampered by
the rapid loss of the enzymatic activity in a diluted solution.
Therefore, we cannot fully exclude the possibility that the D
2,3-
peptides could act as suicide substrates. Such a covalent
enzyme inactivation could possibly proceed by a Michael-type
addition of a nucleophilic group in the enzyme to the a,b-un-
saturated carbonyl.
[17] However, a considerably larger enzyme
preparation will be needed in order for the enzyme–inhibitor
complex to be directly detected and its nature delineated.
In view of this binding behaviour, the dissociation constants
(KD) were derived from simple titration experiments assuming
that the enzyme–inhibitor complex is catalytically inactive.
[18]
For both compounds, within the experimental error, the KD
was found to be 0.94( 0.1) 10
 6m (Figure 2). It is interesting
that peptides IDA and IDF are almost equally potent isomerase
inhibitors, even though the saturated substrate peptides, IA
and IF, differ strongly in their catalytic efficiencies. Given that
the similar hydrophobicities of the Z/E isomers in IDF account
for similar active site binding, this fact suggests that the side
chain substituent at the second position contributes only little
to the transition state binding.
The proposed deprotonation/protonation mechanism neces-
sarily implies the abstraction of a weak acidic proton by a
Scheme 2. Structural comparison of: A) a hypothetical anionic isomerization
intermediate, and B) inhibitor peptide IDA.
Figure 1. Initial reaction velocities as a function of substrate concentration
at various inhibitor concentrations. Without inhibitor (&) and in the presence
of 0.5 mm (*), 1 mm (~), 5 mm (!) and 10 mm (^)I DF, or 0.5 mm (*), 1 mm (~),
5 mm (!) and 10 mm (^)I DA. Substrate was labelled peptide IF. See the Ex-
perimental Section for details.
Figure 2. Scatchard plot for the determination of KD: r is the ratio of the
enzyme activity with bound inhibitor IDF( &)o rI DA( *) to enzyme activity
without inhibitor. Substrate was labelled peptide IF. Error bars represent
standard deviations.
Scheme 1. Proposed two-base-mechanism for the isomerase reaction. The
two catalytic bases are represented by B and B’. When the reaction is per-
formed in D2O, in the presence of substrate, enzyme-bound protons appa-
rently do not exchange with solvent protons.
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group of histidine, from the a-carbon of an amino acid residue
in peptide linkage. The pKa value of an a-proton has been esti-
mated to be higher than 20 but might well approach the
upper limit of enzyme-catalysed proton transfer reactions.
[19]
For the removal of such an a-proton, an enzyme could stabi-
lize a planar enolate anion intermediate of the bound sub-
strate (Scheme 2). Such a strategy has been demonstrated for
the mandelate racemase, a member of the enolate superfamily,
which engages the carbonyl group of mandelate in a low-bar-
rier hydrogen bond and coordinates it to Mg
2+.
[20] Moreover,
recent investigations on an isomerase from the venom of a
spider, which catalyses the stereoinversion of a Ser within a
peptide chain,
[11] make an enolate anion a likely intermediate
in this reaction
[21] (Scheme 2).
Studies of the racemization of free amino acids have indicat-
ed that the reactant side chain group also contributes to the
stability of the enolate anion. Aryl side chain groups, such as
phenylglycine (Phg), can stabilize an intermediate enolate
anion primarily by resonance.
[22] In a similar manner, Met en-
hances the stability of the enolate by orbital overlap.
[23] Indeed,
studies on the enzyme-catalysed isomerization of various
model peptides have shown that the highest observed relative
reaction rates were obtained with peptides containing either
of these residues at position two.
[24]
A deprotonation/protonation mechanism is also utilized by
several cofactor-independent amino acid racemases. Consistent
with the idea of a planar transition state, these reactions are
well known to be inhibited by planar intermediate analogues.
An example is the inhibition of proline racemase by the planar
compound pyrrole-2-carboxylic acid.
[25] Furthermore, planar en-
amine and imine species have been shown to serve as potent
inhibitors of the enzymes diaminopimelate epimerase and glu-
tamate racemase.
[26] Finally, the spider isomerase is also inhibit-




The platypus enzyme, on the other hand, was shown to be
inhibited by amastatin but not by the related bestatin, both of
which are competitive aminopeptidase inhibitors.
[12,27] The N-
terminal residue of these compounds is either an aliphatic
(amastatin) or an aromatic (bestatin) a-hydroxy-b-amino acid.
Therefore, the different side chains were suspected to also de-
termine the activity of the inhibitors and their binding to the
active site.
[27] Both compounds only have a similar, relatively
weak effect (Ki>10
 4m) on the reaction catalysed by the frog
isomerase (Figure 3). It seems likely that those inhibitors with a
b-amino acid bind to the active site in a substrate-like manner,
albeit with the a
2-carbon in an improper position for catalysis.
Conversely, in the case of the unsaturated analogues, their
tight binding to the enzyme as well as a high tolerance against
the side chain of residue 2 suggest that they bind to the transi-
tion state conformation of the enzyme, once more emphasis-
ing the importance of geometry for catalysis.
Taken together, peptides containing an unsaturated amino
acid as the second residue effectively inhibit the stereoinver-
sion catalysed by the Bombina isomerase; this supports the
notion of a planar transition state during this reaction. These
are the first specific inhibitors to be described for this enzyme.
These specific inhibitors supplement the set of tools available
for studying this isomerase, which at present is very limited,
mostly because attempts to express the enzyme in different
over-expression systems have been unsuccessful. Therefore,
these inhibitors could prove even more useful in future investi-




2,3-Ala-Gly-Pro-Val-Leu-amide (IDA): IDA was
synthesized with a selenocysteine (Sec)-containing peptide with
subsequent oxidative elimination.
[28] Thereby, Ile-Sec-Gly-Pro-Val-
Leu-amide was synthesized by PSL (Heidelberg, Germany) on a
continuous flow synthesizer using standard Fmoc solid phase
chemistry with a Rink Amide AM resin (200–400 mesh,
0.62 meqg
 1; Nova-Biochem), PyBOP (benzotriazol-1-yloxytripyrroli-
dinophosphonium hexafluorophosphate) as condensation reagent
and N-methylmorpholine as a base. After cleavage, treatment with
H2O2 (4 equiv in acetonitrile/H2O) yielded a dehydroalanine at the
second position. The peptide was purified by reverse-phase HPLC
over a C-18 column (Vydac) with a linear gradient of acetonitrile
(solvent A, 0.1% TFA; solvent B, 80% acetonitrile) and their mass
was determined by MALDI-MS. Found m/z 566.3 [M+H]
+, calcd
m/z 566.4 [M+H]
+ (Figure S4 in the Supporting Information).
Synthesis of Ile-D
2,3-Phe-Gly-Pro-Val-Leu-amide (IDF): The pep-
tide IDF was synthesized through modified Erlenmeyer–Plçchl and
Bergmann syntheses.
[29] Briefly, Boc-Ile-(dl-3-phenylserine) was syn-
thesized by condensation of Boc-Ile-OH (1.0 g, 4.32 mmol) with
dl-3-phenylserine (1.4 g, 5.52 mmol) by using N-methylmorpholine
(477 mL, 4.33 mmol) and isobutyl chloroformate (566 mL,
4.33 mmol) in solution. The dipeptide (1.6 g, 4.07 mmol) was dried
and ethylacetate extracted at pH 3. For the synthesis of the azlac-
tone, freshly distilled acetic anhydride (3.34 mL) and anhydrous
sodium acetate (0.33 g, 4.08 mmol) were added to the dipeptide.
Figure 3. Inhibition by: A) bestatin, and B) amastatin. HPLC chromatogram
after 10 min reaction of 100 mm labelled peptide IF (l) in the absence (left)
or presence (right) of 100 mm inhibitor; product is represented by D.
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recrystallised and dried. Azlactone (16.85 mg, 47.0 mmol) was cou-
pled to solid-phase prepared Gly-Pro-Val-Leu-amide (2.26 mg,
5.9 mmol) in dichloromethane (1 mL) with triethylamine (50.2 mmol)
and dried. The peptide was deprotected after purification by RP-
HPLC with TFA (50%) in acetonitrile and purified by RP-HPLC and
resulted in 0.92 mg of IDF( Z and E isomers could not be separat-
ed). The product was characterized by ESI-IT-MS (m/z 642 [M+H]
+;
Figure S4 in the Supporting Information) and NMR spectroscopy.
The TOCSY spectrum is shown in Figure S5 in the Supporting Infor-
mation. The chemical shifts of the resonances of the assignment
are listed in Table S1 in the Supporting Information.
Enzyme preparation: Skin secretion from Bombina orientalis was
collected and processed as described.
[9] Briefly, the glycoprotein
fraction eluted from ConA–Sepharose with methylmannoside was
passed over a Sephacryl S-300 column (20 mm HEPES/NaOH buffer,
pH 7.6, 1 mm EDTA), fractions with isomerase activity were subse-
quently passed over SP–Sepharose and the flow-through was frac-
tionated over Q-Sepharose after adjustment to pH 8.6 with NaOH.
The enzyme was eluted with a gradient of NaCl (1–2.5 mm in
20 mm HEPES/NaOH, 1 mm EDTA, pH 8.6). Active concentrated frac-
tions were once more chromatographed over SP- and Q-Sepharose
under the same conditions, and yielded considerably narrower
peaks of activity. Every single fraction was then tested for enzymat-
ic activity, and the protein’s molecular weight was determined by
SDS-PAGE. Highest enzymatic activity coincided with an apparently
homogeneous protein of 52 kDa molecular mass. The enzyme con-
centration was 8.9 mgmL
 1 as determined by UV absorption at
280 nm. The extinction coefficient e=54445m
 1cm
 1 was calculat-
ed with the ProtParam tool (http://expasy.org/tools/protparam.
html) assuming that both Cys residues form cystines. The specific
activity was 224 nmolh
 1mg
 1 at 100 mm substrate IF, pH 6.5 and
378C.
Deuterium incorporation experiment: Substrate IF (100 mm) was
incubated with enzyme (89 mgmL
 1) in phosphate buffer (50 mm)
in
2H2O containing EDTA (5 mm)a t3 7 8C at pD 6.5 in
2H2O. After 5,
10, 20, 30, 50, 70 and 90 min, aliquots of the solution were ana-
lysed by RP-HPLC (218TP C-18 column, Vydac, Hesperia, CA, USA)
with a linear gradient of acetonitrile (solvent A, 0.1% TFA; sol-
vent B, 80% acetonitrile), which was started after a delay of 5 min
in order to remove bulk D2O. The UV absorbance was recorded at
214 nm. Substrate as well as product peaks were collected,
vacuum-dried twice, and redissolved in order to remove deuterium
incorporated into backbone amides. The isotope pattern was then
quantitatively analysed on a MALDI-TOF/TOF 4800 Analyzer (AB
Sciex, Canada) operated in reflector positive mode acquiring 1000–
2000 total shots per spectrum with a laser intensity of 3000–3500
with a-cyano hydroxylcinnamic acid as a matrix. Spectra were ac-
quired and processed by using 4800 Analyzer and Data Explorer
Software.
Inhibition experiments: The substrate in the inhibition assays was
either unlabelled peptide IF (Ile-Phe-Gly-Pro-Ser-Arg-Ser-amide) or
Ile-Phe-Gly-Pro-Ser-Arg-Cys-amide (PSL), which was coupled via the
SH group to the fluorophor Bodipy FL IA [(4,4-difluoro-5,7-dimeth-
yl-4-bora-3’,4’-adiaza-S-indacene-3-propionyl)-N-iodoacetylethylene-
diamine; Invitrogen]. Substrate and inhibitors at the given concen-
trations were incubated with aliquots of the enzyme (44.5 mgmL
 1)
at 378C at pH 6.5 in phosphate buffer (50 mm) containing EDTA
(5 mm) and analyzed by RP-HPLC (218TP C-18 column, Vydac, Hes-
peria, CA) with a linear gradient of acetonitrile (solvent A, 0.1%
TFA; solvent B, 80% acetonitrile). Unlabelled peptides were detect-
ed by UV absorbance at 214 nm. Fluorescence emission of the la-
belled peptides was excited at 480 nm and recorded at 514 nm.
Peaks were integrated with Beckman System Gold Software. Data
from three independent experiments were combined. Some ex-
periments were performed with peptide IA (Ile-Ala-Gly-Pro-Ser-Arg-
Ser-amide) as a substrate.
Enzyme reactivation was tested by dilution of pretreated (50 mm in-
hibitor) enzyme into 100-fold volume buffer or 50 mm inhibitor
(final enzyme concentration 22.25 mLmL
 1) and subsequent deter-
mination of the isomerase activities with the standard assay. Addi-
tional controls were treated equally, except for the addition of in-
hibitor. For testing the effect of amastatin or bestatin (Sigma), the
isomerization rate of labelled peptide IF (10 or 100 mm) was deter-
mined in the presence of inhibitor at concentrations equal to that
of the substrate.
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